source
- Summit Therapeutics' ivonescimab shows improved survival trend in extended follow-up, easing investor doubtsA new analysis of Summit Therapeutics and Akeso's dual‑acting cancer immunotherapy ivonescimab indicates that the drug's impact on overall survival has grown with longer observation. The extended d…
- Summit and Akeso sharpen case for ivonescimab with new Western dataSummit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistic…